MSP-2020
Pharmaceutical compound
From Wikipedia, the free encyclopedia
MSP-2020 is a psychedelic drug of the tryptamine and pyrrolidinylmethylindole families related to psilocybin which is under development for the treatment of mental disorders such as major depressive disorder.[1][2][3][4][5][6][7] It is taken orally.[1] The drug acts as a serotonin 5-HT2A receptor agonist and is described as a prodrug.[1][3][8] It is a 3-pyrrolidine–indole derivative and hence cyclized tryptamine and is said to be psilocybin-like but with stronger effects and a shorter duration.[1][5][6][7] MSP-2020 was originated by Mindset Pharma and is now under development by Otsuka America Pharmaceutical, which acquired Mindset Pharma in January 2024.[1][2][3][4] As of January 2026, MSP-2020 is in phase 1 clinical trials for major depressive disorder.[1][2][3] MSP-2020 was patented by Mindset Pharma in 2021, though its specific chemical structure has not been disclosed and is unclear.[1][7][5][6]
- None
| Clinical data | |
|---|---|
| Other names | MSP2020 |
| Routes of administration | Oral[1] |
| Drug class | Serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
